Clinical Overview

Atrial tachycardia (AT) is a fast heart rhythm driven from a site in the atria outside the sinus node, producing a single, consistent non-sinus P-wave morphology at a fast, usually regular atrial rate (Liwanag and Willoughby, StatPearls, 2023). StatPearls and the LITFL ECG library both treat “atrial tachycardia” and “focal atrial tachycardia” as functionally interchangeable names for this presentation when a single ectopic focus is driving the rhythm (Burns and Buttner, LITFL ECG Library, 2024). Three mechanisms can produce it: enhanced automaticity (an ectopic focus depolarizing on its own accelerated schedule, the most common driver), triggered activity (afterdepolarizations tied to calcium handling), and micro-reentry (a small self-sustaining circuit that can be hard to distinguish from an automatic focus on a surface ECG) — a 2022 cohort of ablated focal ATs found automaticity or triggered activity behind 94% of cases and micro-reentry behind the remaining 6% (Compagnucci et al., Journal of Clinical Medicine, 2022).

This dataset’s SNOMED CT coding treats “AT” as the general atrial-tachycardia concept and reserves a separate label, “EAT,” for a narrower “ectopic atrial tachycardia” concept that a much smaller group of records carries. Most clinical sources use “ectopic,” “focal,” and plain “atrial tachycardia” as overlapping or interchangeable terms for a single-focus, non-sinus atrial rhythm (Burns and Buttner, LITFL ECG Library, 2024; SNOMED CT US Edition), so a strip carrying either label in this dataset should be read as an atrial tachycardia, not assumed to differ mechanistically from the other. [CLINICAL REVIEW NEEDED: no public documentation of the source dataset’s own annotation protocol specifies what, if anything, distinguished an “AT”-labeled record from an “EAT”-labeled one at the point of labeling.]

Focal AT is generally a benign rhythm, but sustained or frequent episodes carry real downstream risk: incessant or high-burden AT can produce tachycardia-induced cardiomyopathy, with associated heart-failure symptoms such as dyspnea, edema, and chest discomfort (Liwanag and Willoughby, StatPearls, 2023; Compagnucci et al., Journal of Clinical Medicine, 2022). Population prevalence is not well established, but it is described as an uncommon SVT subtype overall, accounting for roughly 10-15% of supraventricular-tachycardia ablation referrals (Liwanag and Willoughby, StatPearls, 2023). Episodes can be brief and paroxysmal or persistent for hours to days, and — reassuringly — atrial tachycardia is not considered a lethal arrhythmia in isolation, even though it can be symptomatically bothersome (Liwanag and Willoughby, StatPearls, 2023).

Symptoms track the ventricular rate and how long the episode lasts: palpitations, lightheadedness, presyncope, chest pressure, and shortness of breath are the most commonly reported complaints, and many episodes are entirely asymptomatic — first identified incidentally on telemetry or a Holter recording, including during sleep (Liwanag and Willoughby, StatPearls, 2023; Cleveland Clinic, 2025). Infants and young children more often present nonspecifically, with vomiting, feeding difficulty, or rapid breathing rather than reported palpitations (Cleveland Clinic, 2025).

Recognized triggers and risk factors include stimulants (caffeine, nicotine, cocaine), alcohol use and withdrawal, digoxin toxicity, electrolyte disturbances, hypoxia and underlying pulmonary disease, heightened sympathetic tone from acute illness or stress, structural or ischemic heart disease, and atrial scarring from prior cardiac surgery or ablation (Liwanag and Willoughby, StatPearls, 2023; Cleveland Clinic, 2025). Digoxin toxicity in particular produces a recognizable variant, “atrial tachycardia with block,” in which the ectopic focus fires rapidly while AV conduction is intermittently blocked (Burns and Buttner, LITFL ECG Library, 2024).

Interpretation Guide

Key Features:

• Atrial rate roughly 100-250 bpm, with unifocal/automatic forms often running toward the faster end of that range (Liwanag and Willoughby, StatPearls, 2023; Burns and Buttner, LITFL ECG Library, 2024)
• Ventricular rhythm follows AV conduction: regular at a fixed 1:1 ratio when conduction keeps pace with the atrial rate, or intermittently irregular when AV block — physiologic at very fast atrial rates, or digoxin-induced — drops some atrial beats (Liwanag and Willoughby, StatPearls, 2023)
• P waves: a single, consistent non-sinus morphology — upright or inverted depending on where the ectopic focus sits — clearly different from the patient’s own sinus P wave, and separated from neighboring P waves by a flat, isoelectric baseline, unlike atrial flutter’s continuous sawtooth pattern (Burns and Buttner, LITFL ECG Library, 2024)
• PR interval: variable; may appear short, or the P wave may sit far enough from the preceding QRS that the RP interval is the more useful measurement, depending on the atrial rate and AV conduction (Liwanag and Willoughby, StatPearls, 2023)
• QRS complex: narrow and normal in morphology unless a pre-existing bundle branch block or rate-related aberrant conduction is present (Burns and Buttner, LITFL ECG Library, 2024)
• ST segment and T waves are not primary diagnostic features of atrial tachycardia
• QT interval is not a primary diagnostic feature at these rates; treat any measurement as provisional until the rhythm slows or converts
• Other findings: a gradual “warm-up” (acceleration) at onset and “cool-down” (deceleration) at termination is characteristic of the automatic mechanism behind most focal AT (Liwanag and Willoughby, StatPearls, 2023). Adenosine transiently blocks the AV node and can unmask the underlying atrial activity without terminating the tachycardia itself, unlike its typically rhythm-terminating effect in AV-node-dependent reentrant SVT (Burns and Buttner, LITFL ECG Library, 2024)

The most useful bedside clue is the pattern of onset and offset rather than the rate itself: a tachycardia that visibly speeds up over its first several beats and slows before stopping points toward an automatic focus, while a rhythm that switches on and off at a fixed rate points toward a reentrant circuit such as AVNRT, AVRT, or atrial flutter. Because electrical cardioversion targets a reentrant circuit and does little for an automatic focus that simply restarts itself, mistaking the mechanism at the bedside can lead toward a shock that will not hold (Liwanag and Willoughby, StatPearls, 2023).

Key Leads

• Lead V1 — the single most useful lead for distinguishing a right- from a left-sided focus: a predominantly positive (upright) P wave in V1 favors a left atrial origin, while a negative or biphasic P wave favors a right atrial origin (Feldman and Kalman, European Cardiology Review, 2010). A 2021 update to this 12-lead P-wave morphology framework correctly localized the anatomic region of origin in 93% of focal ATs (Kistler et al., JACC: Clinical Electrophysiology, 2021), and a 2023 paced-template study extended the same approach with comparably high accuracy (Damaty et al., Pacing and Clinical Electrophysiology, 2023).
• Leads II, III, and aVF — the inferior leads help separate a superior atrial focus (upright inferior P waves) from an inferior focus (low-amplitude or inverted inferior P waves) (Feldman and Kalman, European Cardiology Review, 2010).
• A comparison tracing in sinus rhythm — not a lead, but the most useful adjunct: the defining finding is a P wave that looks different from the patient’s own baseline sinus P wave, which is easiest to confirm against a prior strip. This condition is not lead-agnostic — V1 and the inferior leads carry disproportionate weight for localization — but the core recognition (a discrete, non-sinus P wave preceding each QRS, at a rate that often warms up and cools down) can be made from any lead with a clear baseline.

Differential Diagnosis

• Atrial Flutter — also produces a fast, often regular rhythm, but flutter’s atrial waves run together in a continuous sawtooth pattern with no isoelectric baseline between them, versus AT’s discrete P waves separated by a flat baseline at a comparatively slower atrial rate.
• Supraventricular Tachycardia (SVT) — the broader umbrella that AT sits inside; the AV-node-dependent forms most often labeled “SVT” at the bedside (AVNRT, AVRT) are reentrant and start and stop abruptly, while AT is typically automatic and shows a gradual warm-up and cool-down.
• Sinus Tachycardia — the P wave keeps the patient’s normal sinus morphology (upright in I, II, and aVF) and the rate drifts gradually with activity, fever, pain, or volume status, whereas AT’s P wave is a distinct, non-sinus morphology that stays constant once the tachycardia is established.
• Atrial Fibrillation — no organized, repeating P wave at all, with an irregularly irregular ventricular response, versus AT’s single consistent P-wave morphology and a ventricular response that is typically regular or predictably blocked.

Treatment Brief

Confirm lead placement and capture a longer strip whenever a new fast, narrow-complex rhythm appears, and note whether the rate visibly warms up and cools down at onset and offset — that detail helps the receiving provider distinguish an automatic focus from a reentrant SVT before any intervention is chosen. Correlate the rhythm with vital signs and symptoms, and notify the provider for a new or hemodynamically significant finding.

Because most focal AT is driven by an ectopic focus firing on its own schedule rather than a reentrant circuit, standalone electrical cardioversion tends not to hold — “electrical cardioversion without concurrent medical therapy will likely result in arrhythmia recurrence” (Liwanag and Willoughby, StatPearls, 2023). First-line management instead targets the underlying trigger — treating the acute illness, stopping caffeine or other stimulants, correcting a digoxin level, or addressing an electrolyte imbalance — alongside ventricular rate control with beta-blockers or non-dihydropyridine calcium channel blockers (Liwanag and Willoughby, StatPearls, 2023; Cleveland Clinic, 2025). Persistent or recurrent episodes may need a Class IA, IC, or III antiarrhythmic, and catheter ablation is the guideline-recommended definitive therapy for recurrent or incessant focal AT (Compagnucci et al., Journal of Clinical Medicine, 2022), offering low complication rates and a high, durable cure rate — historically reported between 69-100% (Feldman and Kalman, European Cardiology Review, 2010) and still described as “a very high cure rate” today (Cleveland Clinic, 2025). Adenosine can help sort out the mechanism at the bedside — it transiently blocks the AV node without reliably terminating an automatic AT, unlike its typical termination of AV-node-dependent reentrant SVT (Burns and Buttner, LITFL ECG Library, 2024) — but does not substitute for capturing a clean strip for later review.